环磷腺苷葡胺联合麝香保心丸治疗慢性肺源性心脏病合并心衰的疗效观察

doi:10.3969/j.issn.1671-7171.2020.06.030

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨环磷腺苷葡胺联合麝香保心丸治疗慢性肺源性心脏病合并心衰的疗效。【方法】选取2017年1月30日至2018年10月30日本院收治的110例慢性肺源性心脏病合并心衰患者,根据随机数表法将其分为观察组(环磷腺苷葡胺+麝香保心丸,n=55)和对照组(环磷腺苷葡胺,n=55)。比较两组治疗前后肺功能指标[1秒用力呼气容积(FEV1)、1秒用力呼气容积/用力肺活量(FEV1／FVC)]、血气分析指标[动脉血氧饱和度(SaO₂)、动脉血氧分压(PaO₂)]及心脏功能指标[左室射血分数(LVEF)、左室舒张末期内径(LVD)、心输出量(CO)、左室收缩末期内径(LVS)],比较两组治疗临床疗效及不良反应发生情况。【结果】观察组总有效率为96.36%(46/55),高于对照组的83.64%(53/55),差异有统计学意义(χ²=4.946,P=0.026)。治疗后,两组SaO₂、PaO₂、FEV1、FEV1／FVC均高于治疗前,对照组SaO₂、PaO₂均高于观察组,差异有统计学意义(P<0.05);两组FEV1、FEV1／FVC比较,差异无统计学意义(P>0.05)。治疗后,对照组LVEF高于治疗前,观察组LVEF、CO高于对照组,LVD、LVS低于对照组,差异有统计学意义(P<0.05)。两组患者均有7例(12.7%)发生不良反应,经对症处理后好转,两组比较差异无统计学意义(P>0.05)。【结论】环磷腺苷葡胺联合麝香保心丸治疗慢性肺源性心脏病合并心衰患者临床疗效较好,可改善患者心脏功能和血气分析指标,且安全性高,值得推广。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	刘雪娇

关键词 ：肺心病/并发症, 心力衰竭/并发症, 环磷腺苷葡胺/投药和剂量

Abstract：【Objective】To observe the efficacy of meglumine adenosine cyclophosphat combined with musk Baoxin pill on the treatment of chronic pulmonary heart disease with heart failure. 【Methods】A total of 110 patients with chronic pulmonary heart disease and heart failure were enrolled. According to the random number table method, the patients were divided into the observation group (55 cases, with treatment of meglumine adenosine cyclophosphat combined with musk Baoxin pill) and the control group (55 cases, with meglumine adenosine cyclophosphat treatment only). Lung function indexes (FEV1, FEV1/FVC), blood gas analysis indexes (SaO₂, PaO₂), cardiac function indicators (LVEF, LVD, CO, LVS) before and after treatment were analyzed. The efficacy, occurrence of adverse drug reactions, and the mortality within 14 days were observed. 【Results】The total effective rate of the observation group at the end of treatment was 96.36%, which was higher than that of the control group (83.64%), the difference was statistically significant (χ²=4.946,P=0.026). After treatment, the parameters of SaO₂, PaO₂, FEV1 and FEV1/FVC in the two groups were higher than those before treatment. Of which, the SaO₂, PaO₂ in the control group were higher than those in the observation group; and the difference was statistically significant (P<0.05). However, there were no significant differences in FEV1 and FEV1/FVC between the two groups after treatment (P>0.05). The LVEF of the control group after the treatment was higher than that before treatment, while both LVD and LVS of the observation group were lower than those of the control group, the differences were statistically significant (P<0.05). There was no significant difference in the incidence of adverse reactions and mortality rate between the control group and the observation group (P>0.05). 【Conclusion】Meglumine adenosine cyclophosphat combined with musk Baoxin pill has good clinical effect on the treatment of chronic pulmonary heart disease with heart failure, which improves the cardiac function and blood gas analysis indicators and reduces pulmonary artery pressure safely.

Key words： Pulmonary Heart Disease/CO Heart Failure/CO Meglumine Cyclic Adenosine Monophosphate/AD

收稿日期: 2019-05-15

PACS:

R541.61

引用本文:

刘雪娇. 环磷腺苷葡胺联合麝香保心丸治疗慢性肺源性心脏病合并心衰的疗效观察[J]. 医学临床研究, 2020, 37(6): 898-900.
LIU Xue-jiao. Therapeutic Effect of Meglumine Adenosine Cyclophosphat Combined with Musk Baoxin Pill on the Treatment of Chronic Pulmonary Heart Disease with Heart Failure. JOURNAL OF CLINICAL RESEARCH, 2020, 37(6): 898-900.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2020.06.030 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2020/V37/I6/898